Pathways involved in the resolution of inflammatory joint disease

Seminars in Immunology

Volumn 27, Issue 3, 2015, Pages 194-199

  Haworth, Oliver ^a   Buckley, Christopher D ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Arthritis; Inflammation; Resolution

Indexed keywords

5,8,11,14,17 ICOSAPENTAENOIC ACID; ACETYLSALICYLIC ACID; CARBON MONOXIDE; CD59 ANTIGEN; DOCOSAHEXAENOIC ACID; INSULIN; LEUKOTRIENE A4; LIPOCORTIN 1; LIPOXIN; MELANOCORTIN; OMEGA 3 FATTY ACID; RESOLVIN E1; UNCLASSIFIED DRUG; AUTACOID; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTHRITIS; EOSINOPHIL; HUMAN; INTESTINE CELL; MACROPHAGE; MONOCYTE; NONHUMAN; REVIEW; TREATMENT RESPONSE; IMMUNOLOGY; INFLAMMATION; JOINT; LIPID METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; ASPIRIN; DOCOSAHEXAENOIC ACIDS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; JOINTS; LIPID METABOLISM; SIGNAL TRANSDUCTION;

EID: 84937513997     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.04.002     Document Type: Review

References (56)

1. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140(6):871-882.
2. Buckley C.D., Gilroy D.W., Serhan C.N. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 2014, 40(3):315-327.
3. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 2007, 7(6):429-442.
4. Filer A., et al. Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils. Arthritis Rheum. 2006, 54(7):2096-2108.
5. Parsonage G., et al. Prolonged, granulocyte-macrophage colony-stimulating factor-dependent, neutrophil survival following rheumatoid synovial fibroblast activation by IL-17 and TNFalpha. Arthritis Res. Ther. 2008, 10(2):pR47.
6. McGettrick H.M., et al. Fibroblasts from different sites may promote or inhibit recruitment of flowing lymphocytes by endothelial cells. Eur. J. Immunol. 2009, 39(1):113-125.
7. Serhan C.N., Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005, 6(12):1191-1197.
8. Savill J., et al. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2002, 2(12):965-975.
9. Flower R.J., Blackwell G.J. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979, 278(5703):456-459.
10. Serhan C.N., Hamberg M., Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. U. S. A. 1984, 81(17):5335-5339.
11. Spite M., et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461(7268):1287-1291.
12. Seki H., et al. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol. 2010, 184(2):836-843.
13. Campbell E.L., Serhan C.N., Colgan S.P. Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators. J. Immunol. 2011, 187(7):3475-3481.
14. Hasturk H., et al. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J. 2006, 20(2):401-403.
15. Bonnans C., et al. Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury. Am. J. Pathol. 2006, 168(4):1064-1072.
16. Haworth O., et al. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol. 2008, 9(8):873-879.
17. Fiore S., Serhan C.N. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J. Exp. Med. 1990, 172(5):1451-1457.
18. Gheorghe K.R., et al. Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res. Ther. 2009, 11(3):pR83.
19. Levy B.D., et al. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J. Clin. Invest. 1993, 92(3):1572-1579.
20. Chiang N., et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 2006, 58(3):463-487.
21. Perretti M., et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 2002, 8(11):1296-1302.
22. Cooray S.N., et al. Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(45):18232-18237.
23. Fukunaga K., et al. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 2005, 174(8):5033-5039.
24. Schwab J.M., et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447(7146):869-874.
25. Serhan C.N., et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995, 34(44):14609-14615.
26. Kronke G., et al. The 12/15-lipoxygenase pathway promotes osteoclast development and differentiation. Autoimmunity 2009, 42(4):383-385.
27. Planaguma A., et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am. J. Respir. Crit. Care Med. 2008, 178(6):574-582.
28. Calder P.C. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?. Br. J. Clin. Pharmacol. 2013, 75(3):645-662.
29. Serhan C.N., et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 2000, 192(8):1197-1204.
30. Serhan C.N., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 2002, 196(8):1025-1037.
31. Hudert C.A., et al. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(30):11276-11281.
32. Connor K.M., et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 2007, 13(7):868-873.
33. Mas E., et al. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 2012, 58(10):1476-1484.
34. Giera M., et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim. Biophys. Acta 2012, 1821(11):1415-1424.
35. Hong S., et al. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 2003, 278(17):14677-14687.
36. Serhan C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 2007, 25:101-137.
37. Krishnamoorthy S., et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(4):1660-1665.
38. Abdulnour R.E., et al. Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(46):16526-16531.
39. Chatterjee A., et al. The pro-resolving lipid mediator Maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells. PLOS ONE 2014, 9(11):pe113480.
40. Haworth O., et al. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A(4) to promote the resolution of allergic airway inflammation. Nat. Immunol. 2008, 9(8):873-879.
41. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 2012, 11(10):763-776.
42. Wittamer V., et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 2003, 198(7):977-985.
43. Chiang N., Arita M., Serhan C.N. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot. Essent. Fatty Acids 2005, 73(3-4):163-177.
44. Cash J.L., et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 2008, 205(4):767-775.
45. Kim N.D., et al. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J. Exp. Med. 2006, 203(4):829-835.
46. Norling L.V., et al. Cutting edge: humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J. Immunol. 2011, 186(10):5543-5547.
47. Lima-Garcia J.F., et al. The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br. J. Pharmacol. 2011, 164(2):278-293.
48. Perretti M., D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 2009, 9(1):62-70.
49. Kao W., et al. A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis. Br. J. Pharmacol. 2014, 171(17):4087-4096.
50. Yang Y.H., et al. Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis. Arthritis Rheum. 2004, 50(3):976-984.
51. Montero-Melendez T., et al. Association between periodontal disease and inflammatory arthritis reveals modulatory functions by melanocortin receptor type 3. Am. J. Pathol. 2014, 184(8):2333-2341.
52. Motterlini R., Otterbein L.E. The therapeutic potential of carbon monoxide. Nat. Rev. Drug Discov. 2010, 9(9):728-743.
53. Chiang N., et al. Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits. J. Immunol. 2013, 190(12):6378-6388.
54. Chi P.L., et al. The CO donor CORM-2 inhibits LPS-induced vascular cell adhesion molecule-1 expression and leukocyte adhesion in human rheumatoid synovial fibroblasts. Br. J. Pharmacol. 2014, 171(12):2993-3009.
55. Levy B.D., et al. Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 2005, 172(7):824-830.
56. Mangino M.J., et al. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 2006, 79(1-2):84-92.